Lucia Mori has a Ph.D. in Microbiology and Immunology from the University of Pisa, Italy. Her background is in molecular immunology and her long-term research interests have centered on antigen-specific recognition by T lymphocytes. She studied the specificity of antigen recognition of T lymphocytes and T cell receptor (TCR) genes at the National Research Council in Milano and at the Basel Institute for Immunology. At Hoffmann-La Roche Headquarters Basel, she established new experimental models to investigate the role of TCR genes in autoimmunity. Since 1994 she was based at the Department of Biomedicine of the University and University Hospital Basel where I have participated in the discovery of self-metabolites stimulating human TCRγδ cells, and of self-lipids stimulating TCRαβ cells, including NKT cells. Between 2010 and 2016 she led a research group focused on “non classical” T cell immunity at the Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR). Since returning to the Department of Biomedicine in Basel, she lead translational immunology projects focusing on cancer immunotherapy by “non classical” T cells. In September 2019, she co-founded ATIcure, later renamed Matterhorn Biosciences, an immuno-oncology biotech company developing therapies based on TCRs targeting disease-specific metabolic profiles. Lucia acted as Chief Scientific Officer until August 2020. Since June 2024, she retired and kept her passion for immunology strong.